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Abstract
BACKGROUND—Women at increased risk of breast cancer (BC) are not widely accepting of
chemopreventive interventions, and ethnic minorities are underrepresented in related trials.
Further, there is no validated instrument to assess the health-seeking behavior of these women
with respect to these interventions.
METHODS—Using constructs from the Health Belief Model, the authors developed and refined,
based on pilot data, the Breast Cancer Risk Reduction Health Belief (BCRRHB) scale using a
population of 265 women at increased risk of BC who were largely medically underserved, of low
SES, and ethnic minorities. Construct validity was assessed using principal components analysis
with oblique rotation to extract factors, and generate and interpret summary scales. Internal
consistency was determined using Cronbach alpha coefficients.
RESULTS—Test-retest reliability for the pilot and final data was calculated to be r = 0.85.
Principal components analysis yielded 16 components that explained 64% of the total variance,
with communalities ranging from 0.50 – 0.75. Cronbach alpha coefficients for the extracted
factors ranged from 0.45 to 0.77.
CONCLUSIONS—Evidence suggests that the BCRRHB yields reliable and valid data that
allows for the identification of barriers and enhancing factors associated with use of breast cancer
chemoprevention in the study population. These findings allow for tailoring treatment plans and
intervention strategies to the individual. Future research is needed to validate the scale for use in
other female populations.
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Introduction
In the year 2008, it is estimated that breast cancer (BC) would account for 26% of all new
cancer diagnoses (i.e. 182,460 BC cases out of 692,000 cancers from all sites), and 15% of
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cancer deaths among women in the United States.1 It will also be the leading cause of
cancer deaths in women between the ages of 20 and 59 years.1 A significant proportion of
these deaths will be among women of minority race/ethnicity and the medically
underserved.1,2 In fact, significant disparities exist in the deaths from BC between African
American and Caucasian women.2,3 The observed disparities are said to be mediated by
delays in diagnoses due to low SES with limited access to and utilization of BC prevention
services4–8, the tendency for some women of African American race/ethnicity to present
with more aggressive BC phenotypes at similar stages when compared with Caucasians9–
11, or a combination of these factors. However, the treatment of women at increased risk of
BC with agents such as tamoxifen or raloxifene has been shown to reduce the risk of
invasive BC by 32 to 49% in various multinational chemoprevention trials 12–14, to prolong
disease-free survival, and to prevent second primary BCs in patients.15,16 In view of this
incontrovertible evidence, the U. S. Food and Drug Administration approved the use of
tamoxifen in 1998 and raloxifene (Evista) in 2007 for BC chemoprevention in eligible
women.17,18 Further, the majority of BCs diagnosed in African American women (over
50%), and in Latinas (over 60%) are estrogen receptor-positive (ER-+ve) 19–21, and thus,
are amenable to chemoprevention. Yet, few of these women who are at increased risk of BC
receive these interventions (3.5%, and 6.5% in the Breast Cancer Prevention Trial and the
Study of Tamoxifen and Raloxifene respectively).12,14 This has been partly due to the
limited inclusion of ethnic minorities in previous BC chemoprevention trials, a situation that
was exacerbated in part by the lack of an adequate risk assessment tool for these
populations, and limited access to information on BC chemoprevention, upon which
informed decisions could have been made.
Currently, based on the search of MEDLINE from 1996 to 2008, there is no published
validated instrument for assessing the health-seeking behavior of ethnic minorities and the
underserved women who are at increased risk of BC with respect to the acceptance of
chemoprevention. While several studies have been published on the attitudes or acceptance
of chemoprevention among women at increased risk of BC22–31, the instruments employed
in these studies were either not validated, or the validity and reliability data were not
published, and most of these studies were not in underserved populations.22,23,25–30 The
existence and use of such an instrument would lead to a better understanding of the barriers
and enhancing factors to the acceptance of this effective preventive option in these
populations, and would lay the foundation for tailored interventions to enhance informed
decision making about the receipt of BC risk assessment, chemoprevention counseling, or
the interventions. This report describes the development and validation of the Breast Cancer
Risk Reduction Health Belief (BCCRHB) scale, which is a multiple-choice assessment
based on the conceptual framework of the Health Belief Model (HBM).32 To this end, data
were collected in a population of mainly ethnic minorities and underserved women who are
at increased risk of BC for testing and revising of the scale.
The use of principal components analysis to assess the construct validity of the BCRRHB
scale is appropriate for deriving scores from clusters of items that are reliable
representations of the latent constructs underlying the HBM (e.g., perceived susceptibility to
BC). 33–35 The estimated factor scores can then be employed in further analyses, such as in
regression models predicting the level of acceptance of BC chemoprevention in the target
populations.33–35 This paper describes the validation of the scale, while the use of factor
scores will be taken up in a later work.
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Methods
Study Population
The assessment of the validity and reliability of the BCRRHB scale was the first specific
aim of the Acceptance of Breast Cancer Chemoprevention Therapy (ABCCPT) Project,
whose goal was to assess the barriers and enhancing factors for the acceptance of
chemoprevention in ethnic minorities, and medically underserved women who are at
increased risk of BC. The study population of the ABCCPT project is comprised of 265
women, who were mainly underserved or of self-reported minority racial/ethnic
backgrounds (African Americans 38.8%, Hispanics 28.6%, or Caucasians 32.6%), at
increased risk of BC, 35 to 86 years of age, and resided in the Houston Texas metropolis and
its surrounding communities. They received BC prevention-related health care services such
as mammograms, clinical breast examination or breast biopsies in the Ben Taub General
Hospital, the Lyndon B. Johnson General Hospital and their respective affiliated clinics, and
the Methodist Hospital Houston Texas between 2004 and 2006. Eligible participants were
women at increased risk of BC as defined by being 60 years of age of older with no other
known risk factors for BC, 35 to 59 years of age with multiple risk factors such as a family
history in first-degree relatives (FDRs), history of multiple breast biopsies for benign breast
diseases, the detection of a pre-malignant lesion such as lobular carcinoma in-situ, atypical
ductal hyperplasia, or atypical lobular hyperplasia, early menarche (i.e. less than 12 years of
age), or late first live-birth (i.e. at or after 35 years of age).36, 37,38 BC patients, women
who had received risk assessment, chemoprevention counseling, or the intervention were
excluded from the study. This was advised by the fact that these women have a higher level
of knowledge of BC and chemoprevention than the target population (i.e. the underserved
women of low SES, who are at increased risk of BC). Women who had limited capacity for
cognitive evaluation (e.g. those with major psychiatric disorders), the terminally ill, those
who were neither fluent in English or Spanish languages, those of other racial/ethnic groups
(since the proportions of eligible women in these subpopulations were too small), or non-
residents of the Houston Texas areas were also excluded. Women were contacted in the
course of their receipt of care, and invited to participate in the study. Eligibility was
ascertained using a pre-recruitment checklist, and written informed consents were obtained
prior to the onset of the telephone interviews. Depending on the respondents’ preference,
trained personnel conducted telephone interviews in English or Spanish, which lasted for 45
to 60 minutes. Data were collected on demographics, socioeconomic characteristics, the 48
initial items of the BCRRHB scale, and on the participants’ personal BC risk factors. The
study was approved by the IRBs of the Baylor College of Medicine, the Methodist Hospital,
and the Harris County Hospital District’s Research Office that oversees research compliance
for the two main county hospitals — the Ben Taub General Hospital and the Lyndon B.
Johnson General Hospital. Further, the questionnaire, and other study documents were
translated into Spanish and approved by the IRBs prior to the onset of the surveys. All
respondents were compensated ($20.00) for their participation. After a mean duration of 12
months, and using computer generated random numbers, a stratified random sample of 38
participants based on race/ethnicity (14.3% of the study population; whites, n=27; non-
whites, n=11)were contacted for the re-test survey.
Instrument Development
The BCRRHB scale was developed to assess the health-seeking behavior of women who
were at increased risk of BC, mainly the underserved, of low SES, or of minority race/
ethnicity with respect to accepting chemoprevention. The scale items were derived from a
series of 3 preliminary focus group discussions conducted on women who were at increased
risk of BC, who resided in Winston-Salem NC. The report of this study has been published
elsewhere.24 Based on the results of the preliminary focus group discussions, further review
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of the literature, the HBM was deemed suitable, and its constructs used to develop the scale
items.39,40 The HBM has been used to develop various instruments for assessing the use of
BC screening services41,42 in similar study populations.42,43 Our a priori hypotheses were
that increased perceived susceptibility to BC, perceived severity of BC, perceived benefits
of the intervention, perceived high self-efficacy or positive cues to actions would directly
correlate with the acceptance of BC chemoprevention. Meanwhile, high perception of
barriers to receiving the intervention would inversely correlate with its acceptance. We used
the 5-response Likert style for all items with responses ranging from “strongly disagree” to
“strongly agree” except where we used “much lower” to “much higher” as responses to
items that assessed their perceived susceptibility to BC. The initial scale comprising of 52
items was validated for content by a panel of experts in clinical epidemiology, Family
Practice and BC chemoprevention, two behavioral scientists, and pre-tested on a convenient
sample of 40 women of diverse ethnic and socioeconomic backgrounds with similar
characteristics as the study population. The review was to ensure the comprehensiveness of
the contents, the appropriate use of the HBM constructs, the enhancement of the readability,
and to reduce ambiguity, and eliminate redundancy. This process resulted in the elimination
of 4 items, and the rewording of all retained items. The revised scale with 48 items had an
eight-grade reading level according to the SMOG formula44, and our respondents indicated
that the scale items were highly readable, and all respondents completed the survey in less
than an hour.
Statistical Analysis
Descriptive statistics were generated including item means, standard deviations, and ranges,
frequencies, percentages, kurtosis, and skewness. Using the Factor Analysis procedure of the
SPSS software version 16, we assessed the adequacy of the dataset for the factor analyses
procedure through the Bartlett’s Test of Sphericity, and Kaiser-Meyer-Olkin’s (KMO) Test
of Sampling Accuracy. The PROC FACTOR of the Statistical Analyses Software (SAS)
program version 9.2 (SAS, Cary NC) was used to conduct the principal component analyses.
The Kaiser rule of eigenvalues >1 and scree plot provided the basis for extracting the
principal components. After the initial components were extracted, we used the PROMAX
option of the SAS PROC FACTOR Procedure to further delineate the respective
components through oblique rotation, to allow the variables to correlate under the respective
factors.34,35 Three items with low factor loadings (i.e. <.40) for the respective factors were
excluded (see Table 3). Using the alpha option in the PROC UNIVARIATE procedure of
the SAS software, we generated the Cronbach alpha reliability coefficients for the BCRRHB
scale, the individual factors, and the retest survey.45
Results
Study Population
The related data from all 265 participants in the Acceptance of Breast Cancer
Chemoprevention Therapy study were included in this analysis. Most of the participants
were 50 years of age or older (85.0%; mean age, 61.0 years), of low literacy level (65.3%
had a high school education or less), of low income status (75.0% earned less than $29,000
per annum), ethnic minorities (67.5%), single (i.e. never married, divorced/separated, or
widowed; 59.3%), unemployed, retired, or on disability benefits (58.8%), and the recipients
of public health insurance (73.8%). (See Table 1). Of the 467 potentially eligible women
who had validated contact information, 82 (17.6%) could not be reached to complete the
survey due to disconnected telephones. Forty two (9.0%) were found to be ineligible due to
histories of BC, or the receipt of BC chemoprevention counseling. This left 343 participants,
of which 265 completed the survey, resulting in a response rate of 77.3%. According to
Nunnally (1978), we have an item to respondents ratio of 1:5.6, which conveyed >90%
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statistical power to differentiate between various principal components.33 Table 2 shows the
means, and standard deviations of the BCRRHB scale items.
Construct Validity
Bartlett’s test of sphericity yielded a statistically significant results (P<.0001), indicating that
the items shared a common variance (i.e. item correlations do not form an identity matrix),
and the KMO Measure of Sampling Adequacy was .686, suggesting that the variables
measured more than one component. Following the PROC FACTOR procedure, we
extracted 16 principal components (see Table 3). These principal components explained
64% of the total variance, with communalities ranging from 0.50 –0.75.
Internal Consistency Reliability
Cronbach alpha coefficient for the scale items was 0.71, and 0.45 – 0.77 for the respective
principal components. Following the retest survey, the Cronbach alpha reliability coefficient
was 0.85.
Discussions
The BCRRHB scale was designed to measure the health seeking behaviors of women at
increased risk of BC, who are medically underserved, of low SES, and mainly of racial/
ethnic minority backgrounds (i.e. African Americans and Latinas). Of the 16 principal
components that were extracted, nine described enhancing factors towards the acceptance of
BC chemoprevention (see Table 3). These findings are consistent with the knowledge that
increased perceived susceptibility to an illness, and highly perceived benefits of an
intervention, work in concert with high self-efficacy and positive cues to bring about the
adoption of primary and secondary prevention services for BC.42,46 However, we also
identified one additional factor the perceived adequacy of one’s health insurance coverage
of BC chemoprevention. This is consistent with our a priori hypothesis and the literature, in
that the lack of adequate health insurance coverage predisposes to the poor utilization of BC
screening and other prevention services. 47 Meanwhile, seven factors describe potential
barriers to the acceptance of BC chemoprevention. These are the perception of the
interventions as personally inconveniencing; concerns about the perceived poor risks/
benefits ratios; concerns about the perceived effects of the interventions on one’s current
health status; concerns about coping with intervention-related procedures or complications;
perceiving oneself as always being healthy; the mistrust of one’s physicians, and the
concerns about the short duration of the interventions. The concerns about the personal
inconvenience of the interventions is consistent with findings from our preliminary study,
where some women expressed concerns about the extra pill loads, or their ability to be
compliant over the duration of the intervention.24 The concerns about the risks/benefits of
the interventions are in line with the fact that some potentially eligible women would have
refused these interventions due to their side effects such as the increased risk of thrombo-
embolic events, or uterine cancers.12,14,23,30 The concerns about the effects of the
interventions on current health status is in accordance with the fact that most eligible women
are in their fourth of higher decades of life, and may be undergoing some physiologic
changes such as menopause, or have cogent comorbidities (e.g. diabetes mellitus,
hypertension, coronary heart disease, etc.) whose treatments may be either precluded, or
interfered with by the interventions respectively.24,48 The remaining three factors--
perceiving oneself as always being healthy; the mistrust of one’s physicians, and the
concerns about the short duration of the interventions are consistent with known
misconceptions in similar populations such as denial of one’s susceptibility to certain
illnesses46, the mistrust of physicians due to past negative events such as the Tuskegee
Syphilis Study24,46,49, and folklore about disease managements.47 These observations are
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particularly important with respect to BC where psychosocial factors such as unfavorable
coping styles and negative emotional responses among others, predict the increased risk of
death.50
The BCRRHB scale has several strengths, namely, to the best of our knowledge, it is the
first validated instrument that is designed to measure the health-seeking behaviors of women
at increased risk of BC, especially, the medically underserved, those of low SES, and ethnic
minorities. It is also pertinent that these persons are underrepresented in BC
chemoprevention trials, while they have higher risk of death from BC.12,14 In spite of the
low literacy level of the study population, the scale demonstrated significant validity with
64% of the total variance explained by the extracted components, high factor loadings
suggesting a high level of correlation between variables that load for the respective
components, and high communalities suggesting that the items shared a common variance.
With a Cronbach alpha of .71, the scale is internally consistent, and thus, reliable. The high
retest reliability coefficient of .85 attests to its consistency over time. While, we desired
fewer components, the larger number of components is not unexpected in a novel field of
study that involves the treatment of hitherto healthy women with agents that are potentially
harmful, and in a study population with a high prevalence of low literacy.23 It is important
to note that the scale would not be valid or reliable for assessing the health-seeking behavior
of women of higher SES, who are adequately insured, and are at increased risk of BC, as it
has not been validated in this subpopulation.
In all, the BCRRHB scale would serve to enhance the accuracy and ease of assessing the
health-seeking behaviors of women who are of low SES, medically underserved, of ethnic
minority backgrounds, and at increased risk of BC. The utilization of this tool would
precede the development of educational interventions tailored to reduce the identified
barriers, and to accentuate the enhancing factors. These would subsequently help these
women make informed decisions about BC chemoprevention. Ultimately, this would help to
reduce the disparate burden of BC mortality that is observed in this subpopulation. This
view is consistent with the observed decline in BC mortality rate due to increased early
detection, and the use of better therapies. 1 Future research would be to revalidate this scale
in a study population of potentially eligible women of middle to high SES with adequate
health insurance coverage.
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Table 1
The distribution of socio-demographic characteristics (n=265)*
Characteristics Number Percent
Age (years)
 <50 39 14.72
 50–59 82 30.94
 60–69 94 35.47
 ≥70 50 18.87
Education
 High school or less 169 65.25
 College 90 34.75
Annual household income
 <$20,000 132 58.41
 $20,000–$29,000 38 16.81
 $ 30,000 56 24.78
Race/ethnicity
 Caucasian 83 32.55
 Hispanic 73 28.63
 African American 99 38.82
Marital status
 Married 105 40.70
 Single 153 59.30
Employment status
 Employed 59 22.96
 Home-maker 47 18.29
 Retired 78 30.35
 Unemployed 33 12.84
 Disabled 40 15.56
Health Insurance
 Public Insurance 152 73.79
 Private Insurance 54 26.21
Regular personal physician
 Yes 209 87.45
 No 30 12.55
# of Mammograms in the past 5 years
 At least 5 237 98.75
 Less than 5 3 1.25
*
Missing numbers were excluded from the analyses.
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Table 2
Descriptive Statistics of items in the Breast Cancer Risk Reduction Health Belief Scale (n=265)
Item no. Content Mean* SD†
Q1 I am confident that I can tolerate tamoxifen therapy‡ 3.21 0.84
Q2 My family would feel better if I took tamoxifen 3.20 0.74
Q3 Taking tamoxifen would give me peace of mind. 3.31 0.91
Q4 I am sure that I will benefit from tamoxifen treatment. 3.30 0.75
Q5 I am confident that I can cope with the periodic clinic visits (twice a year) that the tamoxifen treatment will
require.
3.73 0.74
Q6 I am confident that I can tolerate the hot flashes from tamoxifen therapy. 3.08 0.93
Q7 Therapy with tamoxifen can stop the progress of breast cancer. 3.43 0.83
Q8 I worry that I would forget to take daily doses of tamoxifen. 2.72 1.07
Q9 Taking daily medication would be inconvenient for me. 2.76 1.06
Q10 I am afraid of knowing my risk for breast cancer. 2.84 1.16
Q11 I would not want to take tamoxifen because it increases the risk of birth defects. 2.84 0.99
Q12 A friend told me that taking tamoxifen could reduce my risk for breast cancer. 2.35 0.98
Q13 My doctor advised me that I would benefit from tamoxifen therapy. 2.19 0.89
Q14 I heard on the media that tamoxifen can reduce the risk for breast cancer. 2.83 1.08
Q15 I have never heard of taking tamoxifen to prevent breast cancer. 3.53 1.16
Q16 I had my doctor assess my risk for breast cancer. 3.11 1.11
Q17 Taking tamoxifen may lower a woman’s chance of broken bones. 3.13 0.86
Q18 Taking tamoxifen will help lower levels of my “bad” cholesterol. 3.02 0.85
Q19 Taking tamoxifen can lower a woman’s risk of getting breast cancer. 3.47 0.80
Q20 If I was diagnosed with breast cancer, I think I would be depressed. 3.84 1.04
Q21 I would be more scared by breast cancer than by a diagnosis of heart disease. 3.35 1.14
Q22 To me, breast cancer is a life-threatening disease. 4.16 0.98
Q23 Tamoxifen has some side effects that are unacceptable to me. 3.10 0.81
Q24 My own risk of getting breast cancer is too low to take tamoxifen 2.82 0.94
Q25 I worry that tamoxifen treatment will affect my sex life. 2.78 0.84
Q26 My doctor has not advised me to take tamoxifen. 3.43 1.10
Q27 I am afraid that tamoxifen will make my health worse. 2.96 0.90
Q28 I worry that tamoxifen will make me feel like throwing up. 3.10 0.86
Q29 I would be nervous about taking tamoxifen because of the increased risk of uterine cancer. 3.08 0.97
Q30 I am not sure that I can tolerate uterine biopsies that may be required during tamoxifen treatment. 2.97 0.93
Q31 Having a history of breast biopsy would make my chances of getting breast cancer 3.06 0.93
Q32 Having a benign breast lump would make my chances of getting breast cancer 3.16 0.89
Q33 I think that these efforts to reduce a woman’s risk of breast cancer work. 3.66 0.74
Q34 I am too young to take tamoxifen. 2.57 0.95
Q35 The period of therapy (5 years) is too long. 3.03 0.98
Q36 I have always been healthy. 3.21 1.10
Q37 Having a family history of breast cancer would make my chances of getting breast cancer: 4.10 0.94
Q38 A woman may be permanently disabled after therapy for breast cancer. 2.48 1.00
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Item no. Content Mean* SD†
Q39 I find it difficult to understand the information I received so far about breast cancer risk reduction therapy. 3.05 1.00
Q40 I trust my doctor’s advice about my breast cancer risk. 3.75 0.92
Q41 Early diagnosis and treatment of breast cancer may not always save a woman’s life. 3.60 1.07
Q42 A woman can usually perform her daily life tasks during therapy for breast cancer 3.55 0.96
Q43 The period of therapy (5 years) is too short. 2.67 0.82
Q44 Compared to other women my age, my chance of getting breast cancer is: 3.27 1.00
Q45 I am sure that I have health insurance that would pay for tamoxifen treatment. 2.89 0.97
*
Range = 1 to 5
†
Abbreviation: SD, standard deviations
‡
Responses ranged from “strongly disagree” to “strongly agree” or “much lower” to “much higher.”
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